The Power List 2022 focuses on the top 10 VIPs in three key categories of medicine making
Voting is now open for the 2024 Company of the Year Awards
Suppliers of reagents and buffers need to adhere to quality systems.
Biocatalysis is an increasingly attractive option in pharmaceutical synthesis.
Platinum group (and other precious) metal catalysts are inherently expensive, so why not recover and recycle?
How can companies avoid the risks of HPAPI containment and handling?
How is the Indian pharmaceutical industry adapting to meet new demands?
Newly published research suggests that some excipients may be more "active" than previously thought.
Can a medieval medicament find use as a modern antibacterial?
How can manufacturers avoid frustrating and inadvertent changes to the solid forms of APIs?
It is essential that drug development incorporates the patient view.
We need to optimize and then accelerate HPAPI drug product development. Alyn McNaughton from Lonza tells us more.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.
What’s Happening with CAR T Therapies?
Pharma’s Portal to the Lab of the Future
The Sulforaphane Promise